Clinical Trials Directory

Trials / Completed

CompletedNCT02095925

Cohort Study to Identify Cancer Patients at High Risk of Venous Thromboembolism

Microparticle's Procoagulant Activity to Identify Patients With Cancer and a High Risk for Venous Thrombosis

Status
Completed
Phase
Study type
Observational
Enrollment
900 (actual)
Sponsor
Harry R. Buller · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Cancer patients are at increased risk of deep venous thrombosis and pulmonary embolism, collectively termed venous thromboembolism (VTE). Risk assessment scores for VTE in cancer patients have been previously developed by the groups of Khorana and Vienna CATS. However, routine thromboprophylaxis for ambulatory cancer patients based on these scores is currently not recommended. In the investigators prospective, observational cohort study, the investigators aim to identify cancer patients at high risk for VTE based on clinical characteristics, coagulation biomarkers and the coagulant activity of tissue factor bearing microparticles.

Conditions

Timeline

Start date
2008-07-01
Primary completion
2016-06-01
Completion
2017-01-01
First posted
2014-03-26
Last updated
2017-01-18

Locations

7 sites across 4 countries: France, Italy, Mexico, Netherlands

Source: ClinicalTrials.gov record NCT02095925. Inclusion in this directory is not an endorsement.